Post-IPO Equity - Orgenesis
Investment Firm
Overview
Orgenesis focuses on a novel therapeutic treatment for diabetes by correcting malfunctioning organs with new functional tissues.
Announced Date
Feb 01, 2017
Funding Type
Post Ipo Equity
Highlights
Location
New York, United States, North America
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 Governing Dynamics Venture Capital |
Round Details and Background
Orgenesis raised $16000000 on 2017-02-01 in Post-IPO Equity
Orgenesis focuses on a novel therapeutic treatment for diabetes by correcting malfunctioning organs with new functional tissues.
Company Funding History
9
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Feb 01, 2017 |  Post-IPO Equity - Orgenesis | 1 | - | 16.0M |
| Dec 16, 2015 | Post-IPO Equity - Orgenesis | - | 10.0M | |
| Nov 26, 2014 | Grant - Orgenesis | - | 2.0M | |
| May 13, 2013 | Post-IPO Equity - Orgenesis | - | 1.3M |
Recent Activity
There is no recent news or activity for this profile.